SCHEDULE: Frazier Life Sciences Amends Maze Therapeutics Stake
Beneficial Ownership Report
Frazier Life Sciences funds disclose updated beneficial ownership in Maze Therapeutics, clarifying individual attributions.
Summary
- Frazier Life Sciences Public Fund, L.P. and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively beneficially own 3,352,915 shares of Maze Therapeutics, Inc. Common Stock, representing 7.7% of the class.
- Frazier Life Sciences Public Overage Fund, L.P. and its related entities (FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C.) collectively beneficially own 989,351 shares, representing 2.3% of the class.
- Frazier Life Sciences X, L.P. and its related entities (FHMLS X, L.P. and FHMLS X, L.L.C.), along with James N. Topper and Patrick J. Heron, collectively beneficially own 75,982 shares, representing 0.2% of the class.
- Frazier Life Sciences XI, L.P. and its related entities (FHMLS XI, L.P. and FHMLS XI, L.L.C.) collectively beneficially own 149,026 shares, representing 0.3% of the class.
- The total number of Maze Therapeutics, Inc. Common Stock outstanding used for percentage calculations is 43,797,166 shares, as of May 8, 2025.
- The filing corrects previous attributions, stating that certain individual members of investment committees (Albert Cha, James Brush, Daniel Estes) are not attributed beneficial ownership of the securities held directly by Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences Public Overage Fund, L.P., and Frazier Life Sciences XI, L.P.
Sentiment
Score: 5
Explanation: The filing is a routine amendment to an ownership disclosure, primarily clarifying beneficial ownership attribution. It does not contain information that would significantly alter the perceived financial health or operational outlook of Maze Therapeutics, Inc.
Positives
- Significant institutional ownership by Frazier Life Sciences funds continues to be disclosed, indicating ongoing investment interest in Maze Therapeutics.
Negatives
- The amendment clarifies that certain individuals previously attributed beneficial ownership are no longer considered beneficial owners for specific fund holdings, correcting prior overstatements.
Risks
- No specific risks related to Maze Therapeutics, Inc. are detailed in this ownership disclosure filing.
Future Outlook
Not applicable. This filing is an ownership disclosure and does not contain forward-looking statements or guidance from Maze Therapeutics, Inc.
Industry Context
This filing is a routine disclosure of beneficial ownership by an investment firm in a publicly traded biotechnology company. It reflects an investment position rather than operational or strategic updates within the biotechnology industry.
Stakeholder Impact
- Shareholders: Provides updated information on significant beneficial ownership by institutional funds and clarifies individual attributions, which can influence perceptions of institutional support and insider alignment.
Key Dates
| Date | Description |
|---|---|
| 2025-05-08 | Date as of which 43,797,166 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2025-05-14 | Date of Issuer's Quarterly Report on Form 10-Q filing with the SEC. |
| 2025-06-30 | Date of event which requires filing of this statement (ownership reporting date). |
| 2025-08-14 | Date of signing of this Schedule 13G Amendment No. 3. |
Keywords
Maze Therapeutics, Frazier Life Sciences, Beneficial Ownership, SEC Filing, Common Stock, Institutional Investor, Biotechnology, Healthcare Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.